Summary: ON SALE
Score: 16/20
MOS: 99%
Share Price: $104
Sticker Price: $508,094
Incyte has grown into a global biopharmaceutical company with approximately 1500 employees, including more than 600 world-class scientists who are leading the field of biopharmaceutical research.
In late 2011, they received their first U.S. Food and Drug Administration approval for Jakafi® which is a drug that treats intermediate and high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow.
I find pharma stocks interesting but I’m typically very hesitant because government and healthcare regulations can cause these stocks to become extremely volatile. In other words, everything can be going fine from a revenue-generating perspective and then a new regulation can released that may cause the stock to drop the very next day. Not fun.
If you’re looking for a little more diversification and are open to a little more risk, take a look at ON SALE pharma stocks like Incyte.